Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2016

Open Access 01-12-2016 | Original investigation

Flow cytometric analysis of platelets type 2 diabetes mellitus reveals ‘angry’ platelets

Authors: Prashilla Soma, Albe Carina Swanepoel, Jeanette Noel du Plooy, Thandi Mqoco, Etheresia Pretorius

Published in: Cardiovascular Diabetology | Issue 1/2016

Login to get access

Abstract

Background

The function of platelets have extended way beyond the horizon of haemostasis and thrombosis, and are recognised as active participants in vascular inflammation, as well as in prothrombotic complications of cardiovascular diseases. We describe and compare platelet function in type II diabetes (with and without cardiovascular manifestation) and healthy individuals using scanning electron microscopy and flow cytometry.

Methods

Thirty subjects were recruited per group and informed consent was obtained from all participants. Diabetic patients were recruited from the diabetic clinic of the Steve Biko Academic Hospital (South Africa). Blood samples were drawn from all participants so that platelet specific antigens were analyzed in citrated whole blood. The platelet parameters used in the study were platelet identifiers (CD41 and CD42) and markers of platelet activation (CD62 and CD63).

Results

Results show that, compared to healthy individuals, both diabetic groups showed a significant difference in both platelet identifiers (CD41-PE, CD42b-PE) as well as markers indicating platelet activation (CD62P-PE and CD63-PE).

Interpretation

The flow cytometric data shows that the platelet surface receptors and platelet activation are statistically elevated. This is suggestive of enhanced platelet activation and it appears as if platelets are displaying ‘angry’ behaviour. The lysosomal granules may play a significant role in diabetes with cardiovascular complications. These results were confirmed by ultrastructural analysis.
Literature
1.
Alexandru N, Popov D, Georgescu A. Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res. 2012;129(2):116–26.CrossRefPubMed
2.
3.
Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22(17):1561–71.CrossRefPubMed
4.
Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012;129(3):263–6.CrossRefPubMed
5.
Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci World J. 2014;2014:781857.CrossRef
6.
7.
Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23(12):2131–7.CrossRefPubMed
8.
Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:909154.PubMedPubMedCentral
9.
Padmavathi P, Reddy VD, Maturu P, Varadacharyulu N. Smoking-induced alterations in platelet membrane fluidity and Na(+)/K(+)-ATPase activity in chronic cigarette smokers. J Atheroscler Thromb. 2010;17(6):619–27.CrossRefPubMed
10.
11.
van Rooy M, Duim W, Ehlers R, Buys AV, Pretorius E. Platelet hyperactivity and fibrin clot structure in metabolic syndrome-induced transient ischemic attack: a microscopy and thromboelastography® study. Cardiovasc Diabetol. 2015;14(1):86.CrossRefPubMedPubMedCentral
12.
Muller KA, Chatterjee M, Rath D, Geisler T. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost. 2015;114(3):498–518.CrossRefPubMed
13.
Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P, Watson SP, Lordkipanidze M, Nash GB. The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 2015;26(6):507–20.CrossRefPubMedPubMedCentral
14.
Viswanathan GNZA. Cardiovascular disease in patients with type 2 diabetes mellitus. J Clin Prev Cardiol. 2013;4:185–9.
15.
Saboor M, Moinuddin M, Ilyas S. Comparison of platelet CD Markers between normal individuals and untreated patients with type 2 diabetes mellitus. J Hematol Thromb Dis. 2013;2(123):2.
16.
17.
Vericel E, Januel C, Carreras M, Moulin P, Lagarde M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes. 2004;53(4):1046–51.CrossRefPubMed
18.
Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res. 1996;83(5):341–9.CrossRefPubMed
19.
20.
Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, Mayer H, Grau AJ. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33(11):2570–4.CrossRefPubMed
21.
Pittilo RM. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol. 2000;81(4):219–30.CrossRef
22.
Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the working group on endothelins and endothelial factors of the European society of hypertension. J Hypertens. 2005;23(2):233–46.CrossRefPubMed
23.
Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest. 2007;131(5):1557–66.CrossRefPubMed
24.
Knight-Lozano CA, Young CG, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, Ischiropoulos H, Ballinger SW. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105(7):849–54.CrossRefPubMed
25.
Carty CS, Soloway PD, Kayastha S, Bauer J, Marsan B, Ricotta JJ, Dryjski M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg. 1996;24(6):927–34.CrossRefPubMed
26.
Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92(9):2432–6.CrossRefPubMed
27.
Hunter KA, Garlick PJ, Broom I, Anderson SE, McNurlan MA. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci. 2001;100(4):459–65.CrossRefPubMed
28.
Al-Dahr MHS. Impact of smoking on platelet, coagulation and lipid profile in young male subjects. World Appl Sci J. 2010;11(1):118–23.
29.
Pretorius E, du Plooy J, Soma P, Gasparyan AY. An ultrastructural analysis of platelets, erythrocytes, white blood cells, and fibrin network in systemic lupus erythematosus. Rheumatol Int. 2014;34(7):1005–9PubMed
30.
Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest. 2004;34(3):205–9.CrossRefPubMed
31.
Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation. 1993;88(1):37–42.CrossRefPubMed
32.
McEver RP. P-selectin/PSGL-1 and other interactions between platelets, leukocytes and endothelium. In: Platelets, vol. 2007. San Diego: Elsevier/Academic Press; 2007. p. 231–49.
33.
Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lewis D, Bloom A. Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol. 1983;69(4):254–9.CrossRefPubMed
34.
Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost. 1991;65(5):467–73.PubMed
35.
Nieuwenhuis HK, van Oosterhout JJ, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood. 1987;70(3):838–45.PubMed
36.
Kraft P, De Meyer SF, Kleinschnitz C. Next-generation antithrombotics in ischemic stroke: preclinical perspective on ‘bleeding-free antithrombosis’. J Cereb Blood Flow Metab. 2012;32(10):1831–40.CrossRefPubMedPubMedCentral
37.
De Meyer SF, Schwarz T, Schatzberg D, Wagner DD. Platelet glycoprotein Ibalpha is an important mediator of ischemic stroke in mice. Exp Transl Stroke Med. 2011;3:9.CrossRefPubMedPubMedCentral
38.
Mu FT, Andrews RK, Arthur JF, Munday AD, Cranmer SL, Jackson SP, Stomski FC, Lopez AF, Berndt MC. A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood. 2008;111(9):4580–7.CrossRefPubMedPubMedCentral
39.
Blann AD, Draper Z. Platelet activation as a marker of heart attack. Clin Chim Acta. 2011;412(11–12):841–2.CrossRefPubMed
40.
41.
Metzelaar M, Wijngaard P, Peters P, Sixma JJ, Nieuwenhuis HK, Clevers H. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem. 1991;266(5):3239–45.PubMed
Metadata
Title
Flow cytometric analysis of platelets type 2 diabetes mellitus reveals ‘angry’ platelets
Authors
Prashilla Soma
Albe Carina Swanepoel
Jeanette Noel du Plooy
Thandi Mqoco
Etheresia Pretorius
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2016
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-016-0373-x

Other articles of this Issue 1/2016

Cardiovascular Diabetology 1/2016 Go to the issue

Study protocol

Combined optical coherence tomography morphologic and fractional flow reserve hemodynamic assessment of non- culprit lesions to better predict adverse event outcomes in diabetes mellitus patients: COMBINE (OCT–FFR) prospective study. Rationale and design

Original investigation

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function

Original investigation

Expression of insulin receptor (IR) A and B isoforms, IGF-IR, and IR/IGF-IR hybrid receptors in vascular smooth muscle cells and their role in cell migration in atherosclerosis

Original investigation

Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study

Original investigation

Associations between blood glucose level and outcomes of adult in-hospital cardiac arrest: a retrospective cohort study

Original investigation

Berberine alleviates the cerebrovascular contractility in streptozotocin-induced diabetic rats through modulation of intracellular Ca2+ handling in smooth muscle cells

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits